EGFR and non-small cell lung carcinoma: This critical role for GAK in the maintenance of respiratory function is thought to be the cause of the side effects observed with the EGFR (epidermal growth factor receptor) kinase inhibitor gefitinib, used in the treatment of patients with NSCLC (non-small-cell lung cancer), as GAK is potently inhibited by this drug [7].